ClinicalTrials.gov
public full text
Public Domain
Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery
RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict which patients will respond to treatment. PURPOSE: This laboratory study is looking at prognostic factors in patients receiving tegafur-uracil for stage II colon cancer that was completely removed by surgery.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- ctDNA and TEP Levels in Colon Cancer#1047760
- Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary#803380
- Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer#839837
- Dose-Escalation Study in Advanced Colon Cancer Patients#859127
- Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer#917494
Record · ID 1111766
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive